EyeTech licenses Gilead compound

EyeTech Pharmaceuticals (New York, N.Y.) received exclusive worldwide rights to GILD's aptamer NX 1838 inhibitor of vascular endothelial growth factor (VEGF). EyeTech will develop the compound to trea...